S503
Clinical - Haemotology
ESTRO 2026
Results:
veno-occlusive disease of liver. Transplant related mortality was seen in three patients. One patient expired due to other cause. At last follow up, 11 patients were alive, of which 8 were disease free. At median follow up of 20 months(IQR= 8-35 months), 2 year relapse free survival and overall survival is 65% and 68% respectively. Conclusion: VMAT based TMLI as conditioning regimen as part of ASCT is feasible and is associated with favorable toxicity profile and acceptable early oncological outcomes. Keywords: TMLI, Allogenic stem cell transplant, VMAT Radiotherapy for primary cutaneous DLBCL: a collaborative analysis by the German Society of Radiation Oncology & Dermatological Oncology Working Group Khaled Elsayad 1,2 , Linda Agolli 3 , Ahmed Gawish 1,2 , Liv Weimer 4 , Andre Glowka 5 , Isabel Falke 6 , Kathrin Hering 7 , Nils Nicolay 7 , Marion Wobser 8 , Cora Waldstein 9 , Andrea Baehr 10 , Romy Buettner 11 , Siyer Roohani 12 , Kalinka Radlanski 12 , Michael Daum- Digital Poster Highlight 1034 Marzian 13 , Tilmann Rackwitz 14 , Philipp Linde 15 , Eleni Gkika 16 , Robert Blach 17 , Maike Trommer 16 , Daniel Medenwald 5 , David Krug 18 , Stefanie Corradini 19 , Daniel Habermehl 3 , Hans Theodor Eich 20 1 Department of Radiotherapy and Radiation Oncology,, Marburg University Hospital, Marburg, Germany. 2 Marburg Ion-Beam Therapy Center (MIT), Department of Radiotherapy and Radiation Oncology, Marburg University Hospital, Marburg, Germany. 3 Department of Radiation Oncology, Justus-Liebig- University Giessen, Giessen-Marburg University Hospital, Giessen, Germany. 4 Department of Radiation Oncology, University Medicine Mainz, Mainz, Germany. 5 Universitätsklinik für Strahlentherapie, Universitätsklinikum Magdeburg A.ö.R, Magdeburg, Germany. 6 Department of Radiotherapy and Radiation Oncology, Clemens Hospital, Munster, Germany. 7 Klinik und Poliklinik für Strahlentherapie, Universitätsklinikum Leipzig, Leipzig, Germany. 8 Klinik für Dermatologie und Allergologie, University Hospital Würzburg, Würzburg, Germany. 9 Department of Radiation Oncology, General Hospital of Vienna, Vienna, Germany. 10 Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Hamburg- Eppendorf, Hamburg, Germany. 11 Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Jena, Jena, Germany. 12 Department of Radiation Oncology, Charité - Universitätsmedizin Berlin, Berlin, Germany. 13 Klinik für Strahlentherapie und Radioonkologie, Helios Hospital, Krefeld, Germany. 14 Department of Radiation
The median age of group is 38 years (range: 22-59 years) with male predominance (11:5). The donor profile was Full matched related donor:9 ; Matched unrelated donor:4 ; and Haplo-matched donor:3. The median dose of TMLI was 13.2 Gy / 8 fractions (range 7.2 Gy/ 4 fractions – 13.2 Gy /8 fractions, two fractions per day). Three patients had received prior Prophylactic cranial irradiation. The mean doses to right eye, left eye, lung, right kidney, left kidney, right parotid, left parotid, liver, heart, bladder, rectum and oral cavity were 6.1 Gy, 6.5 Gy, 8.1 Gy, 5.8 Gy, 7 Gy, 9.3 Gy, 9 Gy, 7.4 Gy, 6.7 Gy, 8.3 Gy, 8.5 Gy and 7.2 Gy respectively. Fourteen patients completed planned treatment (over 3-4 days), one patient received 4 fractions (stopped due to persistent hypotension) and one patient had relapsed before starting ASCT. All except one patient had engraftment as expected (Median time for Neutrophils: 14 days; platelets: 13 days) Acute GVHD was seen in three patients (Skin: 2; Gut: 1). Chronic GVHD was seen in one patient (Skin / Gut). Grade II/III mucositis and diarrhea was seen in 10 and 8 patients respectively. One patient developed
Made with FlippingBook - Share PDF online